Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis
In conclusion, the combination of hydroxyurea with ruxolitinib yielded a high clinical response rate and increased ruxolitinib exposure in patients with hyperproliferative forms of M F.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Novella Pugliese,
Claudia Giordano,
Davide Nappi,
Luigiana Luciano,
Claudio Cerchione,
Mario Annunziata,
Beniamino Casale,
Elena Cris à,
Maria Rosaria Villa,
Luca Pezzullo,
Maria Iovine,
Marco Picardi,
Francesco Grimaldi,
Fabrizio Pane,
Vin Tags: ORIGINAL RESEARCH Source Type: research
MedWorm Privacy Policy
Disclaimer
Copyright © MedWorm 2006-2024